VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome
Public ClinicalTrials.gov record NCT01130246. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS).
Study identification
- NCT ID
- NCT01130246
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 5,189 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2010 (Type not available)
- Primary completion
- Mar 2012 (Actual)
- Completion
- Mar 2012 (Actual)
- Last update posted
- Oct 31, 2012
2010 – 2012
United States locations
- U.S. sites
- 83
- U.S. states
- 31
- U.S. cities
- 70
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site 1064 | Birmingham | Alabama | 35205 | — |
| Investigator Site 1063 | Birmingham | Alabama | 35235 | — |
| Investigator Site 1065 | Birmingham | Alabama | 35243 | — |
| Investigator Site 1020 | Huntsville | Alabama | 35801 | — |
| Investigator Site 1133 | Mobile | Alabama | 36608 | — |
| Investigator Site 1019 | Tucson | Arizona | 85724 | — |
| Investigator Site 1132 | Escondido | California | 92025 | — |
| Investigator Site 1087 | Mission Viejo | California | 92691 | — |
| Investigator Site 1005 | Torrance | California | 90502 | — |
| Investigator Site 1079 | Aurora | Colorado | 80012 | — |
| Investigator Site 1006 | Colorado Springs | Colorado | 80909 | — |
| Investigator Site 1050 | Denver | Colorado | 80218 | — |
| Investigator Site 1045 | Denver | Colorado | 80220 | — |
| Investigator Site 1061 | Fort Collins | Colorado | 80528 | — |
| Investigator Site 1054 | Littleton | Colorado | 80120 | — |
| Investigator Site 1140 | Wheat Ridge | Colorado | 80033 | — |
| Investigator Site 1111 | Hartford | Connecticut | 06102 | — |
| Investigator Site 1028 | Newark | Delaware | 19718 | — |
| Inevestigator Site 1074 | Washington D.C. | District of Columbia | 20010 | — |
| Investigator Site 1030 | Washington D.C. | District of Columbia | 20037 | — |
| Investigator Site 1117 | Washington D.C. | District of Columbia | 20422 | — |
| Investigator Site 1022 | Clearwater | Florida | 33756 | — |
| Investigator Site 1051 | Clearwater | Florida | 33756 | — |
| Investigator Site 1112 | Fort Lauderdale | Florida | 33316 | — |
| Investigator Site 1049 | Lakeland | Florida | 33805 | — |
| Investigator Site 1124 | Miami Beach | Florida | 33140 | — |
| Investigator Site 1095 | Tallahassee | Florida | 32308 | — |
| Investigator Site 1058 | Tampa | Florida | 33613 | — |
| Investigator Site1110 | Atlanta | Georgia | 30342 | — |
| Investigator Site 1011 | Augusta | Georgia | 30901 | — |
| Investigator Site 1114 | Macon | Georgia | 31201 | — |
| Investigator Site 1086 | Naperville | Illinois | 60540 | — |
| Investigator Site 1125 | Oak Lawn | Illinois | 60453 | — |
| Investigator Site 1044 | Covington | Louisiana | 70433 | — |
| Investigator Site 1069 | New Orleans | Louisiana | 70112 | — |
| Investigator Site 1066 | New Orleans | Louisiana | 70115 | — |
| Investigator Site 1144 | Shreveport | Louisiana | 71101 | — |
| Investigator Site 1060 | Flint | Michigan | 48532 | — |
| Investigator Site 1136 | Novi | Michigan | 48374 | — |
| Investigator Site 1137 | Petoskey | Michigan | 49770 | — |
| Investigator Site 1048 | Traverse City | Michigan | 49684 | — |
| Investigator Site 1034 | Duluth | Minnesota | 55807 | — |
| Investigator Site 1046 | Minneapolis | Minnesota | 55407 | — |
| Investigator Site 1033 | Minneapolis | Minnesota | 55417 | — |
| Investigator Site 1016 | Tupelo | Mississippi | 38801 | — |
| Investigator Site 1027 | Kalispell | Montana | 59901 | — |
| Investigator Site 1092 | Missoula | Montana | 59802 | — |
| Investigator Site 1032 | Omaha | Nebraska | 68131 | — |
| Investigator Site 1031 | Ridgewood | New Jersey | 07450 | — |
| Investigator Site 1057 | Johnson City | New York | 13790 | — |
| Investigator Site 1101 | Charlotte | North Carolina | 28204 | — |
| Investigator Site 1100 | Gastonia | North Carolina | 28054 | — |
| Investigator Site 1121 | Raleigh | North Carolina | 27609 | — |
| Investigator Site 1088 | Raleigh | North Carolina | 27610 | — |
| Investigator Site 1123 | Wilmington | North Carolina | 28401 | — |
| Investigator Site 1075 | Winston-Salem | North Carolina | 27103 | — |
| Investigator Site 1108 | Fargo | North Dakota | 58122 | — |
| Investigator Site 1024 | Canton | Ohio | 44710 | — |
| Investigator Site 1143 | Cleveland | Ohio | 44106 | — |
| Investigator 1141 | Cleveland | Ohio | 44109 | — |
| Investigator Site 1131 | Mansfield | Ohio | 44901 | — |
| Investigator Site 1004 | Oklahoma City | Oklahoma | 73104 | — |
| Investigator Site 1026 | Oklahoma City | Oklahoma | 73112 | — |
| Investigator Site 1122 | Portland | Oregon | 97239 | — |
| Investigator Site 1107 | Danville | Pennsylvania | 17822 | — |
| Investigator Site 1029 | Doylestown | Pennsylvania | 18901 | — |
| Investigator Site 1134 | Lancaster | Pennsylvania | 17602 | — |
| Investigator Site 1018 | York | Pennsylvania | 17405 | — |
| Investigator Site 1072 | Providence | Rhode Island | 02906 | — |
| Investigator Site 1038 | Rapid City | South Dakota | 55701 | — |
| Investigator Site 1138 | Sioux Falls | South Dakota | 57104 | — |
| Investigator Site 1014 | Jackson | Tennessee | 38305 | — |
| Investigator Site 1047 | Knoxville | Tennessee | 37917 | — |
| Investigator Site 1115 | Dallas | Texas | 75216 | — |
| Investigator Site 1040 | Dallas | Texas | 75226 | — |
| Investigator Site 1037 | Houston | Texas | 77030 | — |
| Investigator Site 1130 | Houston | Texas | 77030 | — |
| Investigator Site 1025 | Tyler | Texas | 75501 | — |
| Investigator Site 1139 | Layton | Utah | 84041 | — |
| Investigator Site 1056 | Harrisonburg | Virginia | 22801 | — |
| Investigator Site 1083 | Norfolk | Virginia | 23507 | — |
| Investigator Site 1043 | Richmond | Virginia | 23249 | — |
| Investigator Site 1042 | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 279 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01130246, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 31, 2012 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01130246 live on ClinicalTrials.gov.